Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
The DOI matches its Crossref record.
Abstract
3031 Background: Stromal signature regulated by TGF-β pathway is one of the major mechanisms of tumor immune surveillance, leading to resistance to immune checkpoint inhibitors (ICI). Moreover, TGF-β responsive signatures (TBRS) of stromal cells have been associated with poor prognosis. Vactosertib (TEW-7197) is a potent, highly selective, oral inhibitor of TGFBR1. The safety, anti-tumor effect of vactosertib and its association with TBRS levels were evaluated in patients with advanced solid tumors. Based on in-house TCGA analysis, high fibroblast TBRS (F-TBRS) levels were seen in pancreatic, lung, colorectal (CMS4 subtype), and stomach (GS subtype) cancers in association with poor prognosis (adjusted hazard ratio 1.27; P = 1.06 x 10-8). Methods: 29 patients were enrolled in a phase I modified 3+3 dose-escalating study (NCT02160106) and received vactosertib once daily at the dose range of 30~340 mg for 5 days with 2 days off. RNA sequencing of pre-treatment tumor samples in 16 patients were analyzed to evaluate F-TBRS levels defined as geometric mean values of 171 corresponding gene expressions. Results: Vactosertib was safe and well tolerated, and the maximum tolerated dose was not determined. The most common treatment-related AE (TRAE) was fatigue, while G3/4 abdominal pain, AST elevation, and pulmonary edema were each reported in one patient, respectively. One DLT of stroke was seen at 100mg QD. In per-protocol analysis, 6 out of 17 patients who received ≥140 mg achieved stable disease (35.3%) and showed higher F-TBRS levels than those with progressive disease. Conclusions: Vactosertib, a potent and highly selective oral TGFBR1 inhibitor, showed excellent safety with the current dosing schedule. Furthermore, since high F-TBRS levels are well recognized as one of the main mechanisms related to resistance to ICI, vactosertib would be an ideal therapeutic strategy in combination with ICIs or conventional anti-tumor therapies for solid tumors with high F-TBRS levels. Clinical trial information: NCT02160106.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
“This inhibitor displayed a favorable safety profile and antitumor efficacy in phase 1 clinical trials for patients with advanced solid tumors or desmoid tumors.(219,220) Phase 1 clinical trial investigation of this inhibitor for patients with refractory multiple myeloma/metastatic CRC/ metastatic PDAC and phase 2 stud…”
BackgroundOvercoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Metadata
- Authors
- Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H., Baek, I., Ha, I., Ock, C.-Y., Nam, S. Y., Kim, M., Park, N., Kim, J. Y., & Kim, S.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-05-20
- Volume
- 36
- Issue
- 15_suppl
- Pages
- 3031-3031
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2891904106
- Cited by
- 33
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3031
- The paper
- Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H., Baek, I., Ha, I., Ock, C.-Y., Nam, S. Y., Kim, M., Park, N., Kim, J. Y., & Kim, S.-J. (2018). Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.